D. Cunningham

发表

Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study

M. Aresu, S. Chua, I. Chau, 2022, Current oncology.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

K. Savage, Y. Oki, J. Radford, 2018, New England Journal of Medicine.

Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.

J. Neoptolemos, J. Graham, P. Ghaneh, 2022, The lancet. Gastroenterology & hepatology.

SelectingPatientsWith LocallyAdvancedRectal Cancer for NeoadjuvantTreatmentStrategies

David Cunningham, D. Cunningham, 2013 .

High‐grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis

D. Catovsky, A. Wotherspoon, E. Matutes, 2008, British journal of haematology.

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study

S. de Vos, J. Radford, K. Ardeshna, 2022, EClinicalMedicine.

1226P Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay

K. von Loga, R. Petty, I. Chau, 2022, Annals of Oncology.

1209P A phase II study of regorafenib in combination with nivolumab in patients with recurrent or metastatic solid tumors: Results of the ESCC cohort

B. Keam, I. Waxman, S. Pernot, 2022, Annals of Oncology.

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

T. Phillips, P. Lugtenburg, M. Hutchings, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone

D. Cunningham, J. Mansi, C. Viner, 1990, Hematological oncology.

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.

D. Cunningham, P. Clarke, F. Raynaud, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.

B. Coiffier, T. Lister, M. Ghielmini, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastroesophageal junction adenocarcinoma

E. Smyth, M. Davidson, D. Cunningham, 2016 .

A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.

H. Mackay, R. Glasspool, D. Cunningham, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience.

A. Horwich, A. Wotherspoon, D. Cunningham, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

' s response to reviews Title : Gemcitabine based combination chemotherapy in advanced pancreatic cancer-Indirect comparison

Catrin Tudur Smith, J. Neoptolemos, P. Ghaneh, 2008 .

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.

T. Hickish, A. Wotherspoon, D. Cunningham, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. British

A. Maraveyas, J. Bridgewater, C. Dive, 2018 .

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study

D. Demarini, M. Trněný, R. Lynch, 2023, EClinicalMedicine.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

K. Savage, Y. Oki, J. Radford, 2018, The New England journal of medicine.

A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma.

J. Radford, K. Ardeshna, D. Cunningham, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.